Cadrenal Therapeutics will be engaging with the FDA in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients. Left Ventricular Assist Devices – LVADs – are mechanical pumps to support heart function in patients with advanced heart failure.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVKD:
- Cadrenal Therapeutics Inc trading resumes
- Cadrenal Therapeutics Inc trading halted, volatility trading pause
- Cadrenal Therapeutics Inc trading halted, news pending
- Cadrenal Therapeutics Partners with Abbott on Cardiac Trial
- Cadrenal Therapeutics and Abbott partner to develop anticoagulant tecarfarin
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue